Welcome to our dedicated page for Artivion SEC filings (Ticker: AORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Digging through Artivion’s FDA updates, clinical-trial costs, and global device revenues can feel overwhelming when each SEC report stretches well past 200 pages. Whether you are tracking new aortic stent graft approvals or trying to spot shifts in mechanical heart-valve demand, the technical language in an Artivion annual report 10-K or a fresh 10-Q quarterly earnings report often masks the insights that drive decisions.
Stock Titan solves this problem. Our AI engine turns every filing into plain-English takeaways—Artivion SEC filings explained simply. Get instant alerts the moment an Artivion 8-K material event lands on EDGAR, skim AI-generated risk highlights, or drill straight into segment revenue tables without sifting through footnotes. Need to monitor management’s sentiment? Real-time dashboards surface Artivion Form 4 insider transactions so you can gauge executive conviction ahead of pivotal FDA milestones.
The platform covers every document type investors ask about:
- 10-K sections on product liability and clinical data—already summarized and compared year-over-year.
- 10-Q snapshots for revenue growth by valve, graft, and adhesive lines—ideal for quick Artivion earnings report filing analysis.
- 8-K event briefs that explain recall notices or trial results in minutes.
- Proxy statements outlining Artivion executive compensation and option grants.
- Form 4 dashboards showing Artivion insider trading Form 4 transactions in real time.
Jean F. Holloway, SVP and General Counsel of Artivion, Inc. (AORT), reported securities transactions dated 08/12/2025. She exercised stock options covering 16,975 underlying shares with a conversion/exercise price of $26.24 (option grant dated 02/19/2021, vesting 33 1/3% per year and first exercisable on 02/19/2021). On the same date she sold 16,975 shares at a weighted-average price of about $43.011 and an additional 6,381 shares at about $43.018. The filings show her beneficial ownership moved from 195,485 shares to 178,510 and then to 172,129 shares following the reported transactions. Footnotes disclose the weighted-average sale price ranges and offer to provide per-price details on request.
John E. Davis, Chief Commercial Officer of Artivion, Inc. (AORT), exercised 10,802 stock options with an exercise price of $26.24 per share and acquired 10,802 common shares on 08/12/2025. He then sold the same 10,802 shares at a weighted-average price of $43.673, with reported sale prices ranging $43.470–$43.835.
Following these transactions Mr. Davis beneficially owns 208,778 shares. The exercised options were from a grant dated 02/19/2021 that vests 33 1/3% per year and expires 02/19/2027. The filing notes detailed per-price sale information is available upon request.
Artivion, Inc. (AORT) filed a Form 144 reporting a proposed sale of common stock. The filing shows 10,802 shares intended for sale on 08/12/2025 through Morgan Stanley Smith Barney LLC on the NYSE with an aggregate market value of $471,752.51. The issuer's outstanding shares are listed as 47,183,658.
The securities were acquired on 08/12/2025 through a stock option exercise from the issuer and paid in cash. The filer reports "Nothing to Report" for securities sold during the past three months. The notice includes the standard representation that the seller does not possess undisclosed material adverse information about the issuer.
Artivion, Inc. (AORT) has a Form 144 notice reporting a proposed sale of 23,356 common shares with an aggregate market value of $1,004,605.97. The sale is listed as occurring approximately on 08/12/2025 on the NYSE through Morgan Stanley Smith Barney LLC.
The filing shows how the shares were acquired: 6,381 as restricted stock on 02/19/2019 and 16,975 via a stock option exercise on 08/12/2025 paid in cash. The form also discloses multiple insider sales in May 2025 by JEAN F HOLLOWAY, including transactions on 05/21/2025 and 05/27/2025, each with listed share amounts and gross proceeds. The filer affirms no undisclosed material adverse information.
Juniper Investment-affiliated reporting persons amended their Schedule 13D to report a decrease in their beneficial ownership of Artivion, Inc. common stock to 1,864,449 shares, representing approximately 4.0% of outstanding shares as of the record date. Between June 17, 2025 and August 11, 2025 Juniper Targeted Opportunities, L.P. sold 233,715 shares in the open market for an aggregate sale price of approximately $9,540,725, which includes brokerage commissions. Percentages are calculated using 47,183,656 shares outstanding as of August 1, 2025.
The filing breaks out ownership by entity: Juniper Fund holds 1,473,656 shares (about 3.1%), Juniper Targeted Opportunities holds 377,308 shares (about 0.8%), and Juniper Multi-Strategy holds 13,485 shares (about 0.0%). Juniper Investment Company and the named managing members may be deemed to beneficially own the aggregate shares but disclaim ownership for other purposes. The amendment references a Joint Filing Agreement and a schedule of transactions as exhibits.
Amy Horton, Vice President and Chief Accounting Officer of Artivion, reported exercising 7,992 stock options and selling the same 7,992 shares on 08/08/2025. The options had an exercise price of $29.62 and the shares were sold at $38.49, producing an approximate per-share gain of $8.87. After these transactions she directly owns 146,651 shares.
The sale was effected pursuant to a 10b5-1 trading plan adopted March 13, 2025. The exercised options vest at 33 1/3% per year beginning on the first anniversary of the grant; the first exercisable date was March 5, 2020 and the options expire March 5, 2026.
Artivion, Inc. appointed Lance A. Berry as Chief Operating Officer effective August 11, 2025, while he will continue serving as the company’s Chief Financial Officer, Treasurer and Principal Financial Officer. Mr. Berry, age 53, has been the company’s CFO and Treasurer since December 4, 2023. His compensation as COO and continued CFO includes an annual base salary of $540,000, an annual cash incentive with a bonus target of 70% of base salary, and, starting in 2026, a target equity grant valued at $2,250,000 divided equally between Performance Share Units and Restricted Stock Units.
Marshall S. Stanton, M.D., Senior Vice President, Clinical Research and Chief Medical Officer, notified the company of his decision to retire effective March 31, 2026. The retirement was stated to be not related to any disagreements with the company, and the company expects Dr. Stanton to provide strategic advice and transition services for up to one year following his retirement, with terms of that arrangement still being finalized.
Artivion filed a Form 144 reporting a proposed sale of 7,992 shares of common stock through Morgan Stanley Smith Barney LLC on the NYSE with an aggregate market value of $307,612.08. The filing lists total shares outstanding as 47,183,658 and shows the securities were acquired on 08/08/2025 via a stock option exercise with payment made in cash.
The filer reports “Nothing to Report” for sales in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information. The notice is a formal Rule 144 disclosure of a planned insider sale.
Artivion, Inc. filed a Form S-8 to register 3,570,000 additional shares of common stock for issuance under its 2020 Equity and Cash Incentive Plan. The Board increased authorized Plan shares on March 26, 2025 and stockholders approved the increase on May 13, 2025. The filing incorporates prior S-8 registrations of 2,675,000 and 3,040,000 shares and incorporates specified annual, quarterly and current reports by reference. Signatures execute the registration on August 8, 2025.
Artivion (AORT) Q2-25 10-Q highlights
- Revenue rose 15% YoY to $113.0 m; product sales +19% (notably aortic stent grafts +24%, On-X valves +24%), while preservation services +3%.
- Profitability: Gross margin expanded to $73.1 m (64.7% of sales) vs $63.3 m. Operating income improved 29% to $8.4 m, but six-month operating income fell sharply to $10.5 m (vs $31.8 m) due to higher SG&A (+17%) and a $2.7 m debt-conversion inducement.
- Net income swung to $1.3 m (EPS $0.03) from a $2.1 m loss; YTD net income slipped to $0.8 m (EPS $0.02) vs $5.4 m.
- Cash flow: Operating cash outflow of $1.9 m vs $0.6 m inflow prior year; FCF negative $8.9 m after $6.9 m capex.
- Balance sheet: Long-term debt cut to $215.5 m from $314.2 m after exchanging $99.5 m of 4.25% convertible notes for 4.33 m shares. Total liabilities down $94 m; equity up to $419.9 m. Cash steady at $53.5 m.
- Liquidity & covenants: Company remains within leverage covenant (<6.25x); Term Loan ($190 m) carries 10.6% interest, Revolver drawn $30 m.
- Strategic moves: Amended Endospan option lowers potential acquisition price to $175 m and funds additional $25 m loans (FV $10.3 m). Adopted ASU 2024-04 for debt conversions. OBBBA tax law impact under evaluation.
Overall, Q2 shows solid top-line momentum and deleveraging, offset by weak cash generation, elevated interest costs and mixed preservation-service trends.
FAQ
What is the current stock price of Artivion (AORT)?
What is the market cap of Artivion (AORT)?
